NCT03472573View on ClinicalTrials.gov

Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 9, 2018

Primary Completion Date

August 4, 2021

Study Completion Date

June 9, 2022

Conditions
Recurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia
Interventions
DRUG

Palbociclib

Given PO

DRUG

Dexamethasone

Given PO

Trial Locations (1)

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER